ArticleFrontiers in bioengineering and biotechnology2025
3D-printed polycaprolactone combined with cartilage acellular matrix tissue engineered cartilage scaffold manufactured by low-temperature deposition manufacturing.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tissue-engineered cartilage provides an alternative for tissue repair and reconstruction. Composite scaffolds incorporating acellular cartilage matrix (ACM) and synthetic polymers have shown particular promise for cartilage tissue engineering applications. However, the present composite scaffold has not been considered as a clinically available application due to insufficient mechanical property or inflammatory response. Methods: This study presents the composite scaffold composed of ACM and polycaprolactone (PCL) prepared by the low-temperature deposition manufacturing (LDM). Results: The PCL/ACM scaffold exhibited a Young's modulus of 462 ± 119 kPa and a compressive yield stress of 592 ± 87 kPa. After 2 weeks in vitro, cell viability presents 92.36% ± 13.41% in PCL/ACM scaffold. Quantification through type II collagen immunofluorescence intensity measurements, exhibited a 1.85-fold increase (p < 0.001) in the PCL/ACM group relative to PCL controls. Discussion: Through LDM, the ACM was uniformly bond to PCL, resulting in satisfactory mechanical properties of the scaffold. Additionally, the scaffold had a multi-scale structure including microscale pores and nanoscale pores, which increased the porosity of the scaffold. Finally, cartilage-specific extracellular matrix deposition were successfully regenerated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.